What Are The Risk Factors For Pancreatic Cancer? | Health Tips
Pancreatic cancer is currently the fifth most common form of cancer in the United States and is diagnosed in around 40,000 Americans each year. In most cases pancreatic cancer has an extremely poor survival outcome. Just 1 in 20 people diagnosed with pancreatic cancer will still be alive after five years.
The main reason pancreatic cancer has such a poor survival outcome is that the majority of cases are diagnosed when the cancer is at a very late stage. This is due to the non-specific symptoms associated with pancreatic cancer in its early stages. Early warning signs of pancreatic cancer include pain in the upper abdomen, jaundice, loss of appetite, and weight loss.
There are several risk factors that are known to affect an individuals probability of developing pancreatic cancer. While some of these cannot be changed, several can be influenced by sensible lifestyle and diet modifications.
Here are eleven of the more established risk factors for pancreatic cancer.
Posted using ShareThis
Showing posts with label about breast cancer. Show all posts
Showing posts with label about breast cancer. Show all posts
Sunday, April 25, 2010
Tuesday, April 13, 2010
Immunomedics to Report on Potential Cancer Therapy Products in 8 Presentations at 101st Annual AACR Meeting - MarketWatch
Immunomedics to Report on Potential Cancer Therapy Products in 8 Presentations at 101st Annual AACR Meeting - MarketWatch
MORRIS PLAINS, N.J., Apr 12, 2010 (GlobeNewswire via COMTEX) -- Immunomedics, Inc. /quotes/comstock/15*!immu/quotes/nls/immu (IMMU 3.69, +0.12, +3.36%) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research (AACR), April 17 -- 21, 2010, in Washington, DC.
The spotlight of this year's presentations will be on pancreatic cancer, highlighted by a study correlating the results from a blood test for pancreatic cancer detection with responses to a radiolabeled antibody therapy. Additionally, the Company will introduce new antibody-drug conjugates (ADC) being studied in this cancer. (Please refer to the Company's press release at www.immunomedics.com/news_pdf/2010_PDF/PR01212010.pdf for more information on the new blood test).
Posted using ShareThis
MORRIS PLAINS, N.J., Apr 12, 2010 (GlobeNewswire via COMTEX) -- Immunomedics, Inc. /quotes/comstock/15*!immu/quotes/nls/immu (IMMU 3.69, +0.12, +3.36%) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research (AACR), April 17 -- 21, 2010, in Washington, DC.
The spotlight of this year's presentations will be on pancreatic cancer, highlighted by a study correlating the results from a blood test for pancreatic cancer detection with responses to a radiolabeled antibody therapy. Additionally, the Company will introduce new antibody-drug conjugates (ADC) being studied in this cancer. (Please refer to the Company's press release at www.immunomedics.com/news_pdf/2010_PDF/PR01212010.pdf for more information on the new blood test).
Posted using ShareThis
Subscribe to:
Posts (Atom)